Core Viewpoint - The performance of the China Securities Guangdong-Hong Kong-Macao Greater Bay Area Development Theme Index and its related ETF reflects the market dynamics and investment opportunities within the Greater Bay Area, with notable fluctuations in constituent stocks and overall index performance [1][2]. Group 1: Index Performance - As of February 5, 2026, the China Securities Guangdong-Hong Kong-Macao Greater Bay Area Development Theme Index (931000) decreased by 0.74% [1]. - The Greater Bay Area ETF (512970) also saw a decline of 0.47%, with the latest price at 1.5 yuan [1]. - Over the past six months, the Greater Bay Area ETF has accumulated a rise of 15.97% [1]. Group 2: Stock Performance - Among the constituent stocks, Huayin Securities led with a gain of 10.02%, while Jiejia Weichuang experienced the largest drop at 12.39% [1]. - The top ten weighted stocks in the index account for 44.55% of the total index weight, with China Ping An, Luxshare Precision, and BYD being the top three [2]. Group 3: Trading and Liquidity - The trading volume for the Greater Bay Area ETF was 57.35 million yuan, with an intraday turnover rate of 0.66% [1]. - The average daily trading volume over the past week was 99.55 million yuan [1]. Group 4: Risk and Return Metrics - The maximum drawdown for the Greater Bay Area ETF this year is 5.52%, with a relative benchmark drawdown of 0.02% [1]. - The ETF's Sharpe ratio over the past year is reported at 1.51 [1]. - The tracking error for the ETF over the last three months is 0.022% [1].

Core Insights - The report highlights the contradiction faced during the "14th Five-Year Plan" period, where carbon reduction pressures are increasing while the growth rate of new energy installations is slowing down. The introduction of a national capacity price policy is expected to open up space for new energy installations and support high-yield investment options for power companies during the "14th Five-Year Plan" investment intensity [5][6][9]. Group 1: Energy Storage Industry - The national capacity price policy, issued on January 30, 2026, aims to establish a mechanism that balances power supply stability, green energy transformation, and efficient resource allocation. This policy is expected to support the development of adjustable power sources and enhance the installation of new energy [7][9]. - The report estimates that the demand for energy storage will show a high growth trend, with new energy storage installations expected to reach 66.43 GW and 189.48 GWh in 2025, representing year-on-year increases of 52% and 73% respectively [8][9]. - The capacity price policy is seen as the final piece needed for energy storage development, potentially increasing project returns from approximately 6.5% to over 8% under current subsidy conditions. This is expected to stimulate investment interest from state-owned enterprises in new energy storage projects [8][9]. Group 2: Investment Recommendations - The report suggests prioritizing investments in leading companies involved in energy storage integration and upstream battery cells, recommending firms such as Sungrow Power Supply, Trina Solar, LONGi Green Energy, JinkoSolar, CATL, and Eve Energy. It also advises monitoring companies like Haisum, Sungrow Electric, Canadian Solar, and Penghui Energy [9].

Core Viewpoint - The Medical Health Index (980016) closed at 6134.0 points on February 5, with a slight increase of 0.33%, and a total trading volume of 27.221 billion yuan, indicating active market participation [1] Group 1: Index Performance - On the day, 27 stocks within the Medical Health Index rose, with Pianzaihuang leading with a 4.0% increase, while 23 stocks declined, with Changshan Pharmaceutical experiencing the largest drop of 5.2% [1] - The index's turnover rate was recorded at 1.04%, reflecting the liquidity of the stocks involved [1] Group 2: Top Constituents - The top ten constituents of the Medical Health Index include: - WuXi AppTec (603259) with a weight of 10.68%, closing at 97.11 yuan, up 1.57%, and a market cap of 289.753 billion yuan [1] - Hengrui Medicine (600276) with a weight of 9.56%, closing at 58.16 yuan, up 0.97%, and a market cap of 386.020 billion yuan [1] - Mindray Medical (300760) with a weight of 8.13%, closing at 192.10 yuan, down 0.29%, and a market cap of 232.910 billion yuan [1] - Other notable constituents include Pianzaihuang (600436), Aier Eye Hospital (300015), and Changshan Pharmaceutical (300255) [1] Group 3: Capital Flow - The net inflow of main funds into the Medical Health Index constituents totaled 505 million yuan, while retail investors saw a net outflow of 289 million yuan [1] - Detailed capital flow indicates that WuXi AppTec had a net inflow of 213 million yuan, while Changshan Pharmaceutical faced a significant outflow of 52 million yuan from retail investors [2]

编辑丨巫燕玲 连日来，随着东鹏饮料、国恩科技先后在港股上市，"A+H"再迎扩容，构成了香港新股市场持 续繁荣的一角。 Wind 数据显示，今年以来，截至2月5日，港股市场上市新股15 家，同比增长87.50%，总募 资额513.07亿港元，同比增长757.71%，其中，东鹏饮料以101亿港元的募资金额，成为港股 2026年首个百亿规模的IPO。 尽管香港证监会加强了对IPO申请文件质量的审核，但对于2026年全年港股IPO数量及融资额 均将保持高位这一点，行业早已形成共识。 近日，由沙利文捷利(深圳)云科技有限公司主编，沙利文、捷利交易宝、头豹协作发布的 《2025年香港IPO市场及二级市场白皮书》（简称《白皮书》）显示， 截至2025年底，港股 IPO市场项目储备丰富，新的上市申请不断，拟上市数量超过270家。截至目前，还有9家市值 超过千亿的A股公司正在候场。 记者丨 杨坪 据《白皮书》， 截至2025年12月31日，仍处于有效期内的上市申请数量有277家。 另有龙旗科技、白鸽在线、卓正医疗、北京同仁堂等4家已通过聆讯的公司。递表公司中，包 括93家A+H公司，占比高达33.6%。 从行业分布来看，277 ...

资本市场，现在是冰火两重天。 买科技股的公募，最高年盈利233%，另一方面，持有老登股的基金经理们，逐渐被基民抛弃。 基金行业正在经历一轮大洗牌。本来嘛，基民的钱亏了，基金经理却还拿着高薪和奖金，管理费一分不 少，这事被吐槽很久了。 就在上个月，新规出来，一切都要改变。 文丨金融八卦女特约作者：兴华 · · · 除了医药女神，其他明星基金经理也有翻车的。 四季度，医药女神们纷纷扑街。还有基金持仓紧握老登股的基金经理，被爆出来自己偷偷买了很多科技 股赚了大钱，成了众矢之的。 业绩轮流翻车，去年的基金经理离职人数创下新高，已经达到453人。而基金经理总人数却在持续扩 大，很多年轻的基金经理，83%连上一轮牛市都没经历过。 整个基金行业，正在经历一轮大洗牌。 知名基金经理刘彦春的四季报，普遍亏损在5.8%-7.5%之间，最近五年基本上是腰斩。 尤其是基金的四季报一披露，不少医药女神都扑街了。张韡、赵蓓等管理的医药基都在四季度陷入了亏 损，把上半年的利润吐回去不少。 赵蓓管理的工银前沿医疗A第四季度跌了13.7%，年度回报17%。 张韡管理的添富创新医药A 第四季度跌了15.5%，年度回报为36%。 金笑非的鹏华医药 ...

Group 1 - The core viewpoint of the news is that the Hong Kong IPO market is experiencing significant growth, with a notable increase in the number of new listings and total fundraising amounts in 2026 [1][2][4] - As of February 5, 2026, there have been 15 new IPOs in Hong Kong, representing a year-on-year increase of 87.50%, with total fundraising reaching 51.307 billion HKD, up 757.71% [1] - Eastroc Beverage has become the first IPO in Hong Kong for 2026 to raise over 10 billion HKD, totaling 10.1 billion HKD [1] Group 2 - The "2025 Hong Kong IPO Market and Secondary Market White Paper" indicates that there are over 270 companies planning to list, with 277 valid applications as of December 31, 2025 [2][3] - The majority of these applications are concentrated in the software services, healthcare, and industrial manufacturing sectors, accounting for over 60% of the total [3] - The average number of submissions per company is 1.4, indicating a strong influx of new companies into the Hong Kong market [3] Group 3 - Multiple institutions predict that the Hong Kong IPO market will remain robust in 2026, with estimates ranging from 150 to 200 new listings and total fundraising between 300 billion to 350 billion HKD [5] - Deloitte forecasts approximately 160 new IPOs with a minimum fundraising of 300 billion HKD, while PwC expects around 150 listings with total fundraising between 320 billion to 350 billion HKD [5] Group 4 - In 2025, A-share companies were a significant source for the Hong Kong IPO market, with 19 new A+H companies listed, raising a total of 126.946 billion HKD [6][7] - There are currently 93 A-share companies that have submitted applications to list in Hong Kong, including 10 with a market capitalization exceeding 100 billion RMB [7] Group 5 - The trend of leading mainland enterprises and A+H new stocks listing in Hong Kong is expected to continue in 2026, driven by the demand for international financing channels [8] - The influx of A-share companies is enhancing the quality and attractiveness of the Hong Kong capital market, providing stable cash flow and clear growth logic [8] Group 6 - Recent reforms by the Hong Kong Stock Exchange, including the introduction of the 18A and 18C rules, have significantly increased the market's appeal, particularly for biotech and technology companies [10][12] - The 18A rule has led to a rise in biotech listings, with 16 companies listed in 2025, and 27 companies currently applying under this rule [10][14] - The 18C rule has also attracted numerous unprofitable tech companies, with 5 companies listed in 2025 and a total fundraising of 59.15 billion HKD [13][14]

风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本基金业绩 表现的保证。投资人购买基金，既可能按其持有份额分享基金投资所产生的收益，也可能承担基金投资 所带来的损失。投资人应当认真阅读《基金合同》《招募说明书》等基金法律文件，全面认识本基金的 风险收益特征和产品特性，并根据自身的投资目的、投资期限、投资经验、资产状况等判断基金是否和 投资人的风险承受能力相适应，理性判断市场，谨慎做出投资决策。本材料中相关信息来源于基金管理 人认为可靠的公开资料，相关观点、评估和预测仅反映当前的判断，后续可能有所变化。本材料所含任 何市场观点的内容皆基于相应的假设条件，而任何假设条件都可能随时发生变化。基金管理人不承诺、 不保证任何具有预测性质的市场观点必然得以实现。材料中提及的个股不构成投资推荐或建议。ETF基 金的二级市 ...

Core Insights - The 2025 Hurun China 500 list shows significant growth in company valuations, with TSMC leading as the highest valued private enterprise in China at 10.5 trillion RMB, followed by Tencent and ByteDance [1][9]. Company Performance - TSMC's value increased by 3.5 trillion RMB, driven by strong demand for artificial intelligence, advanced process technology, and a solid market position [3][11]. - Tencent's valuation rose by 1.9 trillion RMB, attributed to strong performance in gaming, advertising, and fintech [3][11]. - ByteDance's value grew by 1.8 trillion RMB, benefiting from advancements in AI [3][11]. - Alibaba's value increased by 1.2 trillion RMB, due to strategic investments in AI and cloud computing, alongside a recovery in traditional e-commerce [4][12]. - CATL's valuation rose by 690 billion RMB, supported by sustained demand in the electric vehicle market [4][12]. - Xiaomi entered the top ten with a valuation increase of 357 billion RMB, driven by growth in its automotive business and premium smartphone sales [4][12]. - Other notable companies include Cambricon, which saw a valuation increase of 370 billion RMB, and NetEase, which grew by 238 billion RMB due to strong gaming performance [4][12]. Industry Trends - The total value of the Hurun China 500 companies increased by 21 trillion RMB (38%) to reach 77 trillion RMB [2][10]. - The semiconductor industry experienced the most significant growth, surpassing the life sciences sector to become the second-largest industry in the list, while industrial products remained the largest [2][10]. - The real estate sector faced the largest decline, followed by retail [2][10]. - The average age of the top 500 companies is 29 years, indicating a relatively young corporate landscape [11]. Geographic Insights - Beijing, Shanghai, and Shenzhen are the top three cities with the most companies on the list, housing 59, 57, and 49 companies respectively [2][10]. - Suzhou emerged as the preferred manufacturing base with 68 companies, while Shanghai was the leading research and development hub with 101 companies [2][10]. New Entrants and Market Dynamics - A total of 95 companies (19%) made it to the list for the first time, with seven companies valued over 100 billion RMB [2][10]. - The threshold for entry into the 2025 Hurun China 500 increased by 7.5 billion RMB to 34 billion RMB, reflecting a 28% rise [2][10].

Strategy Research - The macroeconomic landscape shows a divergence in performance, with strong demand for technology hardware driven by AI infrastructure investment, while chemical prices remain robust due to supply constraints [2][3] - High-end liquor prices are stabilizing, indicating some recovery in consumer spending, although the sustainability of this trend remains uncertain [3][4] Food and Beverage Research - The company Sobo Protein is expected to maintain rapid profit growth in Q4 2025, with projected net profit for 2025 ranging from 178 to 191 million yuan, reflecting a year-on-year increase of 46.89% to 57.62% [8][36] - The company is focusing on high-end manufacturing and energy optimization, which is expected to enhance profitability [37] Automotive Research - The Robotaxi market in China is projected to reach a value of 50 billion yuan, with hardware cost reductions and software iterations driving demand [11][29] - The commercial viability of Robotaxi is approaching a critical point, with both L2 and L4 participants accelerating market penetration [11][29] Consumer Sector - The price of high-end liquor, such as Moutai, has increased by 3.9% for original and 3.0% for bulk, likely due to pre-holiday gifting demand [4][16] - The real estate market remains weak, with significant declines in transaction volumes across major cities, although policies to stabilize the market are being implemented [4][16] Technology and Manufacturing - The price of DRAM storage has shown signs of stabilization, with a slight decrease in DDR4 prices and a slight increase in DDR5 prices, while overall prices remain high [5][17] - Chemical prices continue to be strong, with PX prices increasing by 5.2% [5][17] Logistics and Transportation - Passenger transport demand remains stable ahead of the holiday season, with a slight increase in logistics demand reflected in highway and rail freight volumes [18] - Shipping rates have shown mixed trends, with domestic port throughput increasing, indicating a potential recovery in export activity [18] Industry Tracking: Machinery - The company Hangzhou Steam Turbine has signed its first commercial contract for a self-developed gas turbine, marking a significant step towards industrial application [19][20] - The company is also advancing its "B to A" strategy to enhance financing channels for high-investment R&D projects [21] Industry Research: Pharmaceuticals - The total market value of publicly held pharmaceutical stocks decreased from 397.7 billion to 316.1 billion yuan, indicating a decline in investor confidence [23][24] - The chemical preparation sector remains the largest segment within pharmaceutical holdings, accounting for 37.5% of total holdings [23] Industry Research: Information Technology - The median profit growth for computer companies is significantly higher than revenue growth, indicating a trend of improving profitability despite stagnant sales [25][26] - A notable number of companies are experiencing significant profit declines, highlighting a polarized performance within the sector [26][28]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, indicating a positive outlook based on ongoing technological innovation and demand growth [5][6]. Core Insights - The total market value of pharmaceutical stocks held by public funds decreased from 397.7 billion to 316.1 billion yuan, reflecting a decline of 2.58% from Q3 2025 to Q4 2025. The proportion of pharmaceutical stocks in all public fund holdings fell to 7.95%, down 2.58 percentage points from the previous quarter [6][9]. - The highest proportion of holdings in the pharmaceutical sector is in chemical preparations, other biological products, and medical research outsourcing, which accounted for 37.5%, 20.9%, and 16.4% of the total holdings, respectively [6][13]. - The top five pharmaceutical stocks by market value held by public funds in Q4 2025 were: Heng Rui Medicine (32 billion), WuXi AppTec (30.6 billion), Innovent Biologics (16.7 billion), Mindray Medical (15.2 billion), and CanSino Biologics (10.8 billion) [6][24]. Summary by Sections 1. Pharmaceutical Holdings Proportion - The proportion of pharmaceutical stocks held by public funds decreased to 7.95% in Q4 2025, down from Q3 2025, with a notable decline in non-pharmaceutical public fund holdings [9][10]. 2. Market Value of Pharmaceutical Sub-sectors - In Q4 2025, the market value of pharmaceutical sub-sectors held by public funds was as follows: 1. Chemical preparations: 118.6 billion yuan (37.5%) 2. Other biological products: 66 billion yuan (20.1%) 3. Medical research outsourcing: 51.7 billion yuan (16.4%) 4. Medical devices: 33.3 billion yuan (10.5%) 5. Medical consumables: 9.8 billion yuan (3.1%) [13][12]. 3. Public Fund Heavy Holdings - The number of public funds holding the top five pharmaceutical stocks in Q4 2025 was as follows: Heng Rui Medicine (507 funds), WuXi AppTec (448 funds), Mindray Medical (204 funds), Innovent Biologics (202 funds), and BeiGene (162 funds) [17][21]. - The market value growth of public fund heavy holdings in Q4 2025 saw significant increases for Heng Rui Medicine (+20.1 billion), WuXi AppTec (+5.7 billion), China National Pharmaceutical Group (+5 billion), Yingke Medical (+2.2 billion), and Yuyue Medical (+1.8 billion) [28].